{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:19:03Z","timestamp":1772745543401,"version":"3.50.1"},"reference-count":87,"publisher":"Informa UK Limited","issue":"2","funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["FCT Investigator to G.J.L.B.,Postdoctoral Fellowship, SFRH\/BPD\/103172\/2014 to P"],"award-info":[{"award-number":["FCT Investigator to G.J.L.B.,Postdoctoral Fellowship, SFRH\/BPD\/103172\/2014 to P"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"crossref","award":["Galician Plan for Research, Innovation and Growth"],"award-info":[{"award-number":["Galician Plan for Research, Innovation and Growth"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000288","name":"Royal Society","doi-asserted-by":"publisher","award":["G.J.L.B. is a Royal Society fellow"],"award-info":[{"award-number":["G.J.L.B. is a Royal Society fellow"]}],"id":[{"id":"10.13039\/501100000288","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1080\/13543776.2017.1259411","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T14:48:11Z","timestamp":1478702891000},"page":"179-189","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":32,"title":["Trends in therapeutic drug conjugates for bacterial diseases: a patent review"],"prefix":"10.1080","volume":"27","author":[{"given":"Pedro M. S. D.","family":"Cal","sequence":"first","affiliation":[{"name":",","place":["United Kingdom"]},{"name":"Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal"}]},{"given":"Maria J.","family":"Matos","sequence":"additional","affiliation":[{"name":",","place":["United Kingdom"]}]},{"given":"Gon\u00e7alo J. L.","family":"Bernardes","sequence":"additional","affiliation":[{"name":",","place":["United Kingdom"]},{"name":"Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal"}]}],"member":"301","published-online":{"date-parts":[[2016,11,23]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2014.04.006"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01059-13"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/431892a"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2013.86"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2014.02.002"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.02.009"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm800345u"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24298"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.01.065"},{"key":"e_1_3_3_12_1","unstructured":"Cytogen Corporation. Polymer\/antibiotic conjugate. WO1990\/015628."},{"key":"e_1_3_3_13_1","unstructured":"Helfgott & Karas PC Yissum Res Dev C. Water-soluble polyene conjugate. WO1996\/005212."},{"key":"e_1_3_3_14_1","unstructured":"Competitive Technologies of PA Inc. Amphiphilic polyene macrolide antibiotic compounds. WO1996\/032404."},{"key":"e_1_3_3_15_1","unstructured":"Proctor & Gamble Pharmaceuticals Inc. Antimicrobial quinolonyl lactam esters. US5434147; 1993."},{"key":"e_1_3_3_16_1","unstructured":"Gruppo Lepetit SPA Antibiotics ge 37468 a b and c. WO1994\/014838."},{"key":"e_1_3_3_17_1","unstructured":"Piramal Life Sciences Ltd. Novel antibacterial compounds. WO2007\/119201."},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.48.780"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/md11020387"},{"key":"e_1_3_3_20_1","unstructured":"Piramal Enterprises Limited. Polymeric prodrug conjugates. WO2014\/053873."},{"key":"e_1_3_3_21_1","first-page":"34","article-title":"Effect of the excipient concentration on the pharmacokinetics of PM181104, a novel antimicrobial thiazolyl cyclic peptide antibiotic, following intravenous administration to mice","volume":"4","author":"Yemparala V","year":"2014","unstructured":"Yemparala V, Damre A, Manohar V, et al. Effect of the excipient concentration on the pharmacokinetics of PM181104, a novel antimicrobial thiazolyl cyclic peptide antibiotic, following intravenous administration to mice. Pharma Sci. 2014;4:34\u201341.","journal-title":"Pharma Sci"},{"key":"e_1_3_3_22_1","unstructured":"Micrologix Biotech Inc. Indolicidin and cationic peptides conjugated with polymers. WO1999\/043357."},{"key":"e_1_3_3_23_1","unstructured":"Instituto Biochimico Pavese Pharma SPA. Antibiotic-natural polysaccharide polymer adducts. WO2000\/078287."},{"key":"e_1_3_3_24_1","unstructured":"Biosynexus Incorporated. Antimicrobial polymer conjugates. WO2003\/082926."},{"key":"e_1_3_3_25_1","unstructured":"Ethicon Inc. Antimicrobial composition. WO2007\/014087."},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2003.11.009"},{"key":"e_1_3_3_27_1","unstructured":"The Bionic Ear Institute. Biodegradable polymer-bioactive moiety conjugates. WO2010\/040188."},{"key":"e_1_3_3_28_1","unstructured":"University College Cardiff Consultants Limited. Therapeutic conjugates. WO2012\/035310."},{"key":"e_1_3_3_29_1","unstructured":"Nektar Therapeutics. Polymer-based compositions and conjugates of antimicrobial agents. US8420068; 2013."},{"key":"e_1_3_3_30_1","unstructured":"Oregon Health Sciences University. Covalent polar lipid conjugates with antimicrobial and antineoplastic drugs for targeting to biological protected sites. WO2000\/033883."},{"key":"e_1_3_3_31_1","unstructured":"University of Manitoba. Guanidinylated aminoglycoside-lipid conjugates. WO2012\/004684."},{"key":"e_1_3_3_32_1","unstructured":"University of South Florida. Surfactant-free nanoparticles for drug delivery. WO2008\/085556."},{"key":"e_1_3_3_33_1","unstructured":"Matera Lda. Antimicrobial nanoparticle conjugates. WO2012\/025514."},{"key":"e_1_3_3_34_1","unstructured":"Vyome Biosciences. Conjugate-based antifungal and antibacterial prodrugs. WO2012\/177986."},{"key":"e_1_3_3_35_1","unstructured":"William Marsh Rice University. Fullerene (C60) vancomycin conjugates as improved antibiotics. US2004\/0241173."},{"key":"e_1_3_3_36_1","unstructured":"University of Manitoba. Triazole-based aminoglycoside-peptide conjugates and methods of use. WO2009\/037592."},{"key":"e_1_3_3_37_1","unstructured":"Newsouth Innovations PTY Ltd. Dual action nitric oxide donors and their use as antimicrobial agents. WO2014\/071457."},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00466-1"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2016.1161753"},{"key":"e_1_3_3_40_1","unstructured":"Miles Laboratories Inc. \u03b2-Galactosyl-umbelliferone-labeled aminoglycoside antibiotics and intermediates in their preparation. US4226978; 1978."},{"key":"e_1_3_3_41_1","unstructured":"Technion Research & Development Foundation Ltd. Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes and for inhibition of anthrax lethal factor. US7635685; 2009."},{"key":"e_1_3_3_42_1","unstructured":"MicroCarb Inc. Receptor conjugates for targeting penicillin antibiotics to bacteria. US5466681; 1994."},{"key":"e_1_3_3_43_1","unstructured":"Sense Therapeutic Ltd. Uses of ble proteins and antibiotics from the bleomycin family. WO2004\/046730."},{"key":"e_1_3_3_44_1","unstructured":"Los Alamos National Security LLC. Synthetic analogs of bacterial quorum sensors. US8350061; 2011."},{"key":"e_1_3_3_45_1","unstructured":"University of Notre Dame Du Lac. Anti-bacterial siderophore-aminopenicillin conjugates. US2013\/0281424."},{"key":"e_1_3_3_46_1","unstructured":"Burnet M Guse J-H Kim G. Antibiotic conjugates. US2006\/0069047."},{"key":"e_1_3_3_47_1","unstructured":"Oregon Health Sciences University. Covalent polar lipid conjugates with antimicrobial and antineoplastic drugs for targeting to biological protected sites. WO2000\/033883."},{"key":"e_1_3_3_48_1","unstructured":"Ramot U Yacoby I Ron EZ et al. Targeted drug-carrying viruses. WO\/2006\/095345."},{"key":"e_1_3_3_49_1","unstructured":"Glycovaxyn Ag. Capsular Gram-positive bacteria bioconjugate vaccines. WO2011\/138361."},{"key":"e_1_3_3_50_1","unstructured":"Gmbh FKD Water-soluble antibiotic comprising an amino sugar in the form of a polysaccharide conjugate. WO2003\/000738."},{"key":"e_1_3_3_51_1","unstructured":"Emory University. Oligosaccharide conjugates for targeting bacteria and uses related thereto. WO2012\/097223."},{"key":"e_1_3_3_52_1","unstructured":"Yale University. Antibiotics improved by conjugation with stereospecific carbohydrtes and methods for carbohydrate stereoselectivity. WO1992\/007862."},{"key":"e_1_3_3_53_1","unstructured":"University of Manitoba. Triazole-based aminoglycoside-peptide conjugates and methods of use. WO2009\/037592."},{"key":"e_1_3_3_54_1","unstructured":"Wang H Targeted antibiotic and antimicrobial treatments for personalized administration. US2013\/0183323."},{"key":"e_1_3_3_55_1","unstructured":"Genentech Inc. Anti-wall teichoic antibodies and conjugates. US2015\/0366985."},{"key":"e_1_3_3_56_1","unstructured":"Research Corporation NY. Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections. US4427660; 1982."},{"key":"e_1_3_3_57_1","unstructured":"Allergan Inc. Peptide therapeutic conjugates and uses thereof. WO2010\/063124."},{"key":"e_1_3_3_58_1","unstructured":"National Institute of Immunology. Novel bioconjugates as therapeutic agent and synthesis thereof. WO2007\/108013."},{"key":"e_1_3_3_59_1","unstructured":"Allergan Inc. Antibiotic Conjugates. US2014\/0256658."},{"key":"e_1_3_3_60_1","unstructured":"Allergan Inc. Antibiotic conjugates directly linked with steroid drugs. WO2014\/138350."},{"key":"e_1_3_3_61_1","unstructured":"Allergan Inc. Steroid antibiotic conjugates. WO2014\/138359."},{"key":"e_1_3_3_62_1","unstructured":"Allergan Inc. Antibiotic conjugates linked with steroid drugs. WO2014\/138375."},{"key":"e_1_3_3_63_1","unstructured":"Lehigh University. Methods for the manufacture and use of antimicrobial sterol conjugates. US5834453; 1997."},{"key":"e_1_3_3_64_1","unstructured":"Ophidian Pharmaceuticals Inc. Prevention and treatment of sepsis. WO1994\/014437."},{"key":"e_1_3_3_65_1","unstructured":"Pono Corporation. Prevention and treatment of sepsis. US6660267; 1994."},{"key":"e_1_3_3_66_1","unstructured":"Plc CLS Method for the production of antigenic protein-hapten conjugates and antibodies corresponding thereto. WO1989\/003040."},{"key":"e_1_3_3_67_1","unstructured":"Aktiebolag RBL A pharmaceutical preparation and a conjugate of a bactericide and an antibody directed against plaque forming or caries-inducing bacteria. WO1989\/011866."},{"key":"e_1_3_3_68_1","unstructured":"Kim S Anti-bacterial antibodies and methods of use. US6322788; 1999."},{"key":"e_1_3_3_69_1","unstructured":"Kim S Antibody-conjugated antibodies. US2002\/0168368."},{"key":"e_1_3_3_70_1","unstructured":"Strox Biopharmaceuticals LCC. Anti-staphylococcus aureus antibodies. US2009\/0274704."},{"key":"e_1_3_3_71_1","unstructured":"Strox Biopharmaceuticals LLC. Anti-bacterial antibodies. US2010\/0322944."},{"key":"e_1_3_3_72_1","unstructured":"Strox Biopharmaceuticals LLC. Antibiotic-conjugated antibodies. US7 569 677; 2002."},{"key":"e_1_3_3_73_1","unstructured":"Strox Biopharmaceuticals LLC. Anti-Staphylococcus aureus antibodies. US7795402; 2010."},{"key":"e_1_3_3_74_1","unstructured":"Strox Biopharmaceuticals LLC. Anti-bacterial antibodies. US8142780; 2010."},{"key":"e_1_3_3_75_1","unstructured":"Genentech Inc. Anti-wall teichoic antibodies and conjugates. WO2014\/194247."},{"key":"e_1_3_3_76_1","unstructured":"Genentech Inc. Anti-wall teichoic antibodies and conjugates. WO2014\/193722."},{"key":"e_1_3_3_77_1","unstructured":"Genentech Inc. Anti-wall teichoic antibodies and conjugates. US2015\/0366985."},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature16057"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0714-690"},{"issue":"14","key":"e_1_3_3_80_1","first-page":"77","article-title":"FDA drug approvals","volume":"2015","author":"Mullard A","year":"2014","unstructured":"Mullard A. FDA drug approvals. Nature Rev Drug Discov. 2014;2015(14):77\u201381.","journal-title":"Nature Rev Drug Discov"},{"issue":"15","key":"e_1_3_3_81_1","first-page":"73","article-title":"FDA drug approvals","volume":"2016","author":"Mullard A","year":"2015","unstructured":"Mullard A. FDA drug approvals. Nature Rev Drug Discov. 2015;2016(15):73\u201376.","journal-title":"Nature Rev Drug Discov"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01250.x"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.01754-09"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14098"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05382-11"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00712-12"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00402-10"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1039\/c3sc50862e"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S36243"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2017.1259411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:35:33Z","timestamp":1772742933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2017.1259411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,23]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1080\/13543776.2017.1259411"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2017.1259411","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}